CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new methods to create Antibody-Drug Conjugates (ADCs) with precise control over their structure. By innovating synthetic techniques, the project aims to produce ADCs with varied drug-to-antibody ratios and bi-specific antibodies, enhancing therapeutic options in medicine.
Antibody-Drug Conjugates (ADCs) are revolutionary next-generation therapeutics.
The number of ADCs in the clinic is constantly growing with four of them having now reached the market.
Despite this great promise, the complex structure of antibodies results in drawbacks for their reliable modification to construct ADCs, thus impairing the full potential of ADCs.
One of the major reasons for clinical failure is that it is hard to control the drug to antibody ratio (DAR) to obtain homogeneous struct…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
